Monograph Details
|
|
Neoplasms
> Antimicrotubule agents
|
|
TAXOTERE |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antimicrotubule agent |
| Generic Name |
|
Docetaxel 40mg/mL; soln for IV infusion after dilution; contains polysorbate 80; diluent contains alcohol. |
| Indications |
|
Locally advanced or metastatic breast cancer after failure of prior chemotherapy. In combination with doxorubicin and cyclophosphamide: adjuvant treatment of operable node (+) breast cancer. Locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy. In combination with cisplatin: initial treatment of unresectable, locally advanced or metastatic non-small cell lung cancer without previous chemotherapy. In combination with prednisone: hormone-refractory metastatic prostate cancer. In combination with cisplatin and fluorouracil: advanced gastric adenocarcinoma without previous chemotherapy; induction treatment of locally advanced squamous cell carcinoma of the head and neck. |
| Children |
|
Not recommended. |
| Adults |
|
Give by IV infusion over 1 hour once every 3 weeks. Breast cancer: 60–100mg/m2. Adjuvant in operable node (+) breast cancer (treat for 6 courses), NSCLC, prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma: 75mg/m2. Chemotherapy-naive NSCLC: 75mg/m2. For all: premedicate with oral corticosteroid. Adjust dose based on tolerability and effect (see literature); allow neutrophils and platelets to recover before subsequent cycles. |
| Contraindications |
|
Neutrophil count <1500 cells/mm3. |
| Precautions |
|
Hepatic dysfunction; bilirubin >ULN, SGOT and/or SGPT >1.5XULN concomitant with alkaline phosphatase >2.5XULN: not recommended. Monitor blood (esp CBC), liver function tests. Pre-existing effusions. Pregnancy (Cat.D; use adequate contraception); nursing mothers: not recommended. |
| Interactions |
|
May affect, or be affected by, other CYP3A4 inhibitors, inducers, or substrates (eg, cyclosporine, ketoconazole, erythromycin, troleandomycin). |
| Adverse Reactions |
|
Neutropenia, anemia, febrile neutropenia, hypersensitivity/infusion site reactions, thrombocytopenia, neuropathy, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, GI upset, mucositis, alopecia, myalgia; cutaneous reactions (erythema, edema, desquamation), acute myeloid leukemia, death (septic and nonseptic); others. |
| How Supplied |
|
Single-dose vials (0.5mL, 2mL)—1 (w. diluent, supplies) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
